ÂÜÀòÂÒÂ×

David Garvey is the Preclinical Advisor at Model Medicines. Prior to their current position, David served as the Vice President of Chemistry at Bikam Pharmaceuticals from 2007 to 2011. While at Bikam, David led the development of a potential new treatment for Class II autosomal dominant retinitis pigmentosa (adRP) based on small molecule pharmacologic chaperones. The lead molecule successfully completed preclinical safety toxicology studies under David's leadership.

From 1994 to 2006, David served as the Executive Director of Chemistry at NitroMed. In this role, they directed the company's computational and synthetic medicinal chemistry efforts virtually via CROs to achieve the company's discovery research goals. Additionally, they created the company's intellectual property portfolio by working with counsel to produce patent applications that ensure comprehensive coverage of the novel inventions that emerged from the research effort.

David began their career in 1982 as a Group Leader/Senior Group Leader at Abbott Laboratories. David held this position until 1994 when they joined NitroMed.

Garvey received their Doctor of Philosophy in Organic Chemistry from the Massachusetts Institute of Technology and their Bachelor of Science in Chemistry from Merrimack College.